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ABSTRACT
Introduction: Streptococcus pneumoniae can cause 
invasive pneumococcal diseases (IPD), such as 
bacteremic pneumonia, bacteremia, meningitis, 
and sepsis, and non-IPDs, such as otitis 
media, nonbacteremic pneumonia, and upper 
respiratory tract infections. It was estimated 
in 2000 that, worldwide, S. pneumoniae was 
responsible for 826,000 deaths annually in 
children aged between 1 month and 5 years. 
A 7-valent pneumococcal conjugate vaccine 
(PCV7) was licensed in 2000 in the USA and in 
2001 in Europe.
Methods: A literature search was performed in 
PubMed to identify studies assessing the impact 
of routine childhood PCV7 vaccination on 
pneumococcal morbidity and mortality. Here, 
the impact on IPD is reported.
Results: A total of 37 articles reporting impact 
data on IPD were included in this review: four 
from Australia, 17 from western Europe, and 
16 from North America. In vaccine-eligible 
children in the postvaccination period, a 
reduction ranging from 39.9% in Spain to 99.1% 
in the USA in vaccine-type (VT) IPD incidence, 
compared with the prevaccination period, 
was reported in 18 studies. All but one of the 
30 studies assessing the impact of PCV7 on 
all-type IPD reported a reduction ranging 
from 1.7% in Spain to 76.3% in Australia. 
In addition, the majority of studies reported 
reductions in VT and all-type IPD incidence in 
age groups that were not vaccine eligible.
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eight geographical areas in the USA, the incidence 
of IPD ranged from 19.0 to 29.9 per 100,000 
general population [5]. However, the surveillance 
systems, case definitions, and diagnostic standards 
for IPD in Europe are very heterogeneous making 
direct comparisons difficult.
A 7-valent pneumococcal conjugate vaccine 
(PCV7) was licensed in 2001 in Europe and 
introduced into the national immunization 
programs (NIPs) as a universal childhood vaccine 
in around 2006–2008. Its introduction into the 
NIPs in different countries varied, with some 
countries initially only recommending vaccination 
for high-risk children before generalizing to all 
children (e.g., UK, Germany, and France). PCV7 
was licensed and introduced into the NIP in 2000 
in the USA. In Australia, it was licensed in 2002 
and was initially recommended for high-risk 
children, but in 2005 PCV7 was introduced into 
the NIP for all children.
PCV7 has now been in use for over 
10 years and many studies have reported its 
effectiveness and impact [6–9]. PCV7 has been 
replaced by 13-valent pneumococcal conjugate 
vaccine (PCV13) in many countries, and a 
10-valent conjugate pneumococcal vaccine is 
also available. These higher-valent conjugate 
vaccines include some of the important 
emerging serotypes, while continuing to protect 
against the serotypes in PCV7. In this review, 
the wealth of data available on the impact 
of routine childhood PCV7 in reducing all-
type and vaccine-type (VT) IPD, in vaccine-
eligible (direct effect) and nonvaccine-eligible 
populations (indirect effect) in North America, 
western Europe, and Australia is summarized.
MATERIALS AND METHODS
The data presented are part of a larger global 
literature review that assessed the impact of 
PCV7 in different pneumococcal disease areas. 
Conclusions: The results from this review 
illustrate that PCV7 has had a significant 
impact on IPD across all ages through its use 
in pediatric immunization programs. With 
the introduction of 13-valent pneumococcal 
conjugate vaccine (PCV13) further reductions 
in the incidence of IPD due to the six additional 
serotypes included, as well as continued 
protection against IPD due to PCV7 serotypes 
may be expected. Robust surveillance systems 
are essential for the evaluation of the impact of 
PCV13 on all-type IPD and for monitoring the 
evolution of non-VT IPD.
Keywords: Direct vaccine impact; Immunology; 
Indirect vaccine impact; Infectious diseases; 
Invasive pneumococcal disease; Streptococcus 
pneumoniae ;  Vaccine impact; 7-valent 
pneumococcal conjugate vaccine
INTRODUCTION
Streptococcus pneumoniae is a Gram-positive 
diplococci surrounded by a polysaccharide 
capsule that protects it from the human immune 
system. More than 90 serotypes have been 
identified, with a serotype distribution that 
varies geographically. However, only a limited 
number of serotypes cause invasive pneumococcal 
disease (IPD) throughout the world [1]. 
S. pneumoniae causes invasive diseases, such as 
bacteremic pneumonia, bacteremia, meningitis, 
and sepsis, and non-IPDs, such as otitis media 
and upper respiratory tract infections [2]. It was 
estimated in 2000 that, worldwide, S. pneumoniae
was responsible for 826,000 deaths annually in 
children aged between 1 month and 5 years [3]. 
In 2005, over a 12-month period, 23,470 cases of 
IPD were reported in 18 European countries, with 
the incidence varying from 0.4 in Italy to 20.2 and 
20.3 per 100,000 general population in Finland 
and Denmark, respectively [4]. In 1998–1999 in 
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childhood IPD vaccination were analyzed: 
four from Australia, 17 from western 
Europe, and 16 from North America [10–46]. 
The characteristics of these studies are 
summarized in Table 1 [10–46]. Eight of the 
European studies were from Spain, two each 
from Norway and the UK, and one each from 
Austria, Belgium, Denmark, Germany, and 
the Netherlands [10–26]. Five of the North 
American studies used data from the active 
bacterial core surveillance (ABCs) database; 
they used the same pre pneumococcal 
conjugate vaccine (PCV) vaccination period 
(1998–1999) but analyzed different post-PCV 
vaccination periods and populations [29–33]. 
Two other studies from North America used 
the same database from Alaska; they used the 
same pre-PCV vaccination period (1995–2000) 
The PubMed search was performed using the 
following terms: (pneumonia OR “invasive 
pneumococcal disease” OR IPD OR “otitis 
media” OR death) AND ([pneumococcal AND 
conjugate AND vaccin*] OR PCV).
In this paper, the data on the impact of 
PCV7 vaccination in infants on the incidence 
of IPD (VT and all type) in the general 
population is summarized, in vaccine-eligible 
children (direct effect) and in nonvaccine-
eligible age groups (indirect effect). Studies 
that were published between January 2000 and 
March 2011, and performed in western Europe, 
North America, and Australia were included. 
Before/after studies were included if the impact 
data (percentage change in crude or adjusted 
incidence rates) were provided or could be 
calculated. The calculation used was ([incidence 
prevaccination – incidence postvaccination]/
incidence prevaccination)* 100.
Publications that reported efficacy (i.e., 
randomized clinical trials), modeling or 
health economics studies, studies on specific 
populations (e.g., those with comorbidities, such 
as HIV positive, patients with sickle cell disease), 
and studies in specific locations with unknown 
denominators were excluded.
RESULTS
A total of 1,007 publications were identified 
from the global search, and after two rounds 
of screening 84 were selected for inclusion in 
the global literature review (Fig. 1). The main 
reasons for exclusion were: cohort study with 
no comparative group (epidemiology data); 
modeling or cost-effectiveness studies; only 
specific patient subgroups; review articles; 
and no incidence data or data sufficient for 
calculating incidence (mainly missing data 
on denominator). From these, all 37 articles 
reporting data on the impact of routine 
Fig. 1  Flow diagram describing the literature search in 
PubMed and screening process. aAnalyzed in this paper. 
bSome papers contributed more than one topic. IPD 
invasive pneumococcal disease
Excluded aer  
rst screen
n = 578 (57.4%)
IPD/mortality n = 37a
Pneumonia n = 16
Meningitis n = 16
Bacteremia n = 3
Antibiotic resistance n = 11
Carriage n = 15
Total n = 96b
First screen on titles  
and abstracts
n = 429 (42.6%)
Studies identied in 
PubMed search
n = 1,007
First screen on  
full papers
n = 84 (19.6%)
Excluded aer  
second screen
n = 345 (80.4%)
130 Adv Ther (2013)  30(2):127–51.
Table 1  Summary of characteristics of included studies (continued on next page)
Study ID [ref ], 
country (specic 
area)
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Table 1  continued
Study ID [ref ], 
country (specic 
area)
















from 1997 to 
2007
PCV7 introduced 
in 2001, but in NIP 

















data from nine 
hospitals
PCV7 introduced in 














Data from all 
laboratories in the 
region
PCV7 introduced in 








[20], Spain (two 
hospitals in one 
health district in 
Barcelona region)
Data from two 
hospitals
PCV7 introduced in 




≤5 years All-type IPD
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Table 1  continued
Study ID [ref ], 
country (specic 
area)
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IPD; non-VT 
IPD
Miller 2011 [26], 
UK (England and 
Wales)
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given to the HPA 
and isolates sent to 
HPA reference lab 
for serotyping
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Table 1  continued
Study ID [ref ], 
country (specic 
area)
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Table 1  continued
Study ID [ref ], 
country (specic 
area)
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but analyzed different post-PCV vaccination 
periods [34, 35]. Two of the North American 
studies were from Canada [41, 42]. Four studies 
were from Australia [43–46].
Impact on VT IPD in Vaccine-Eligible Children
The impact of PCV7 on VT IPD in vaccine-eligible 
children (<2 or <5 years old, depending on the 
study) was evaluated in 18 studies (Table 2). 
A reduction in VT IPD incidence was reported 
in all the studies, ranging from 39.9% in 
Spain [23] to 99.1% in the USA [32]; the median 
rate reduction was 90.1%.
Vaccine Impact on All-Type IPD in Vaccine-
Eligible Children
The impact of PCV7 on all-type IPD in 
vaccine-eligible children (<2 years or <5 years 
depending on the study) was evaluated in 
30 studies (three from Australia, 15 from 
Europe, and 12 from North America) (Table 3). 
All but one of the studies reported a reduction 
Table 1  continued
Study ID [ref ], 
country (specic 
area)




















PCV7 (and PPV23) 
introduced universally 
in 2005/2 + 1 (in 1999 
























PCV7 (and PPV23) 
introduced universally 
in 2005/2 + 1 (in 1999 









ABCs active bacterial core surveillance, CDC Centers for Disease Control and Prevention, HPA Health Protection 
Agency, ICD-9-CM International Statistical Classification of Diseases and Health-related Problems, 9th Revision 
clinically modified, ICD-10-CM International Statistical Classification of Diseases and Health-related Problems,  
10th Revision clinically modified, IPD invasive pneumococcal disease, NCKP North Carolina Kaiser Permanente, 
NIP national immunization program, non-VT IPD nonvaccine-type IPD, PCV pneumococcal conjugate vaccine, 
PPV23 23-valent pneumococcal polysaccharide vaccine, ST subtype, VT IPD vaccine-type IPD, VRT IPD vaccine-
related-type IPD
aABCs is run by the CDC and covers a population of 29,757,552 persons in California (San Francisco County and 
children <5 years in Alameda and Contra Costa counties); Colorado (ve county Denver area); Connecticut; Georgia 
(20 county Atlanta area); Maryland (six county Baltimore area); Minnesota; New Mexico; New York (15 county 
Rochester and Albany areas and children <5 years in Erie county); Oregon (three county Portland area); Tennessee  
(20 counties)
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Table 2  Impact on VT IPD in vaccine-eligible populations









Australia ( January 2005 for all <2 years)
Lehmann 2010 [44] Nonaboriginal, 
<2 years (PCV7 
and PPV23)
1997–2001 61.2 2005–2007 6.6 –89.2
Roche 2008 [45] Nonindigenous 
<2 years
2004 73.4 2006 6.7 –90.9
Williams 2011 [46] <2 years 2002–2004 60.9 2007 2.1 –96.6
Europe
Foster 2010, UK (September 
2006) [25]
<2 years 2003–2005 26.4 2006–2009 5.5 –79.2
Miller 2011, UK (September 
2006) [26]
<2 years 2000–2006 40.8 2009–2010 0.9 –97.8
Vestrheim 2008, Norway 
(2006) [15]
<1 year 2004–2005 40.5 2007 3.4 –91.6
1 year 53.7 24.3 –54.7
Hanquet 2011, Belgium 
( January 2007) [11]
<2 years 2002–2003 92.9 2008 4.0 –95.7
Harboe 2010, Denmark 
(2007) [12]
<2 years 2000–2007 36.7 2008 7.7 –79.0
Munoz-Almagro 2008, Spain 
(2001) [23]
<2 years 1997–2001 26.8 2002–2006 16.1 –39.9
Barricarte 2007, Spain 
(2001) [19]
<2 years 2000–2002 56.0 2004–2005 16.0 –71.4
Rodenburg 2010, Netherlands 
(June 2006) [14]
<2 years 2004–2006 24.3 2006–2008 8.0 –67.1
North America (2001 in USA and 2002 in Alberta, Canada)
Hennessy 2005 [34] Nonnative  
<2 years
1995–2000 101.3 2001–2003 20.0 –80.3
Singleton 2007 [35] Nonnative  
<2 years 
1995–2000 101.3 2004–2006 2.3 –97.7
Whitney 2003 [29] <2 years 1998–1999 156.1 2001 33.6 –78.5
CDC 2008 [32] 1 year 1998–1999 177.3 2005 1.6 –99.1
<1 year 144.0 2.7 –98.1
Pilishvili 2010 [33] <5 years 1998–1999 81.9 2007 0.4 –99.5
Tyrrell 2009 [41] <2 years 2000 86.3 2006 4.7 –94.6
Kellner 2009 [42] <2 years 1998–2001 66.4 2003–2007 9.0 –86.4
CDC Centers for Disease Control and Prevention, PCV7 7-valent pneumococcal conjugate vaccine, PPV23 23-valent 
pneumococcal polysaccharides vaccine, VT IPD vaccine-type invasive pneumococcal disease
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Table 3  Impact on all-type IPD reduction in vaccine eligible population (continued on next page)









Australia ( January 2005 for all)
Lehmann 2010 [44] Nonaboriginal 
<2 years
1997–2001 73.8 2005–2007 24.2 –67.2
Roche 2006 [45] General 
population  
<2 years
2002 93.0 2006 22.0 –76.3
Williams 2011 [46] <2 years 2002 98.1 2007 25.1 –74.4
Europe
Verstrheim 2008, Norway 
(2006) [15]
<2 years 2004–2005 67.7 2007 32.6 –51.8
<5 years 36.0 19.7 –45.3
Vestrheim 2010, Norway 
(2006) [16]
<5 years 2004–2005 35.9 2008 9.9 –72.4
Harboe 2010, Denmark 
(2007) [12]
<2 years 2000–2007 54.8 2008 23.8 –56.6
Foster 2010, UK (September 
2006) [25]
<2 years 1995–2005 43.3 2006–2009 22.4 –48.3
2003–2005 35.9 2006–2009 22.4 –37.6
Miller 2011, UK  
(September 2006) [26]
<2 years 2000–2006 54.2 2009–2010 23.6 –56.5
Rückinger 2009, Germany 




1997–2003 20.0 2007–2008 11.0 –45.0
Hanquet 2011, Belgium 
( January 2007) [11]
<2 years 2002–2003 129.7 2008 82.4 –36.5
Rodenburg 2010, 
Netherlands ( June 2006) 
[14]
<2 years 2004–2006 34.5 2006–2008 22.5 –34.8
Rendi-Wagner 2009, Austria 
(2003) [10]
<2 years 2001–2004 12.2 2004–2007 8.7 –28.7
Aristegui 2007, Spain (2001 
– private) [18]
<2 years 1998–2001 93.5 2003 56.3 –39.8
Calbo 2006, Spain (2001) 
[20]
<5 years 1999–2001 96.9 2002–2004 90.6 –6.5
Munoz-Almagro 2008  
(2001 not national, or 
reimbursed) [23]
<2 years 1997–2001 32.4 2002–2006 51.3 +58.3
Perez-Trallero 2009 (late 
2001, not reimbursed) [24]
<5 years 1996–2001 50.0 2002–2007 39.6 –20.8
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Impact on VT IPD in All Ages
The impact of PCV7 on VT IPD in all ages was 
evaluated in nine studies that all reported a 
reduction ranging from 1.4% in the Netherlands [14] 
to 93.5% in the USA [33] with a median reduction 
rate of 65.5% (Table 4). In the study in the 
Netherlands, the periods compared were 2004–
2006 and 2006–2008, so the postvaccination 
period was soon after the introduction of PCV7 
into the NIP in 2006.
in all-type IPD incidence ranging from 1.7% 
(in Spain) [19] to 80.2% in the USA [32], with 
a median rate reduction of 45.0%. The highest 
rate reductions were reported generally in 
North America, Australia, and Norway, and 
the lowest was in Spain; the only study that 
did not report a reduction was performed in 
a single hospital in Barcelona, Spain, which 
reported 198 episodes of IPD in 194 children, 
with an increase of 58.3% between 1997–2001 
and 2002–2006 [23].
Table 3  continued









Barricarte 2007, Spain 
(2001) [19]
<2 years 2000–2002 117 2004–2005 115 –1.7
Guevara 2009, Spain ( June 
2001) [22]
<5 years 2001–2002 82.5 2006–2007 72.4 –12.2
North America (2001 in USA and 2002 in Canada)
Albrich 2007 [27] ≤4 years 1997–2000 139.7 2000–2004 44.1 –68.4
Black 2007 [28] <5 years 1996–2000 62.5 2000–2005 15.3 –75.5
Whitney 2003 [29] <2 years 1998–1999 188.0 2001 59.0 –68.6
Hsu 2005 [36] <5 years 1990–1991 56.9 2001–2003 17.4 –69.4
Hicks 2007 [31] <5 years 1998–1999 95.2 2004 22.6 –76.3
CDC 2008 [32] 1 year 1998–1999 213.6 2005 37.8 –82.3
<1 year 170.5 40.0 –76.5
Pilishvili 2010 [33] <5 years 1998–1999 98.7 2007 23.6 –76.1
Kellner 2009 [42] 6–23 months 1998–2001 77.7 2003–2007 18.0 –76.8
Tyrrell 2009 [41] <2 years 2000 96.7 2006 25.8 –73.3
Hennessy 2005 [34] Nonnatives  
<2 years
1995–2000 131.1 2001–2003 51.0 –61.1
Singleton 2007 [35] Nonnatives  
<2 years 
1995–2000 135.5 2004–2006 43.6 –67.8
Simonsen 2011 [39] <2 years 1996–1999 27.8 2005–2006 5.5 –80.2
2–4 years 5.4 2.0 –63.0
CDC Centers for Disease Control and Prevention, IPD invasive pneumococcal disease, PCV7 7-valent pneumococcal 
conjugate vaccine
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Vaccine Impact on All-Type IPD in All Ages
Data were available from 10 articles from Australia 
(two), western Europe (six) and North America 
(two) (Table 5). The prevaccination rate of all-type 
IPD per 100,000 varied from 4.0 in Germany [13] 
to 24.4 in the USA [33]. The postvaccination rate 
per 100,000 varied from 3.2 in Germany [13] to 
17.1 in Denmark [12]. Eight studies reported a 
reduction in IPD incidence ranging from 9.6% 
in England [25] to 44.7% in the USA [33]; the 
median rate of reduction was 26.8%. The highest 
impact was observed in the USA, Australia, and 
the UK. In the UK, a higher reduction rate was 
observed in the later post-PCV7 period (2009–
2010 vs. 2003–2005). Two studies reported small, 
statistically nonsignificant increases; 3.2% in 
Spain [22] and 6.0% in the Netherlands [14].
Impact on VT IPD in Age Groups not Vaccine 
Eligible (Indirect Effect)
Seven of the eight studies reporting data for 
nonvaccine-eligible children under 17 years 
Table 4  Impact on VT IPD reduction in all ages









Australia ( January 2005 for all)
Lehmann 2010 [44] Nonaboriginal, 
all ages (PCV7 
& PPV23)
1997–2001 5.3 2005–2007 2.2 –58.5
Hanna 2010 [43] Nonindigenous 
people, all ages
2001–2004 6.1 2006–2009 1.4 –77.0
Europe
Foster 2010, UK  
(September 2006) [25]
All ages 2003–2005 4.3 2006–2009 2.2 –48.8
Miller 2011  
(September 2006) [26]
All ages 2000–2006 8.0 2009–2010 1.1 –86.3
Fenoll 2009, Spain  
( June 2001) [21]
<15 years 1996–2001 5.2 2005–2006 2.4 –53.8
Guevara 2010, Spain  
( June 2001) [22]
All ages 2001–2002 5.5 2006–2007 1.9 –65.5
Rodenburg 2010, 
Netherlands  
( June 2006) [14]
All ages 2004–2006 7.0 2006–2008 6.9 –1.4
North America (2001)
Singleton 2007 [35] All ages, 
nonnatives 
1995–2000 8.9 2004–2006 1.3 –85.4
Pilishvili 2010 [33] All ages 1998–1999 15.5 2007 1.0 –93.5
IPD invasive pneumococcal disease, PCV7 7-valent pneumococcal conjugate vaccine, PPV23 23-valent pneumococcal 
polysaccharides vaccine, VT vaccine type
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the same population, a reduction of 40.0% was 
reported [35].
The impact on VT IPD in adults aged 15/17–
64 years was reported in 12 studies for a total 
of 18 age groups. A reduction was reported in 
all studies except one; in the Netherlands an 
increase of 9.9% was reported in those aged 
50–64 years [14]. The reductions reported ranged 
of age showed a reduction in VT IPD ranging 
from 40.0% in children aged 5–17 years in Spain 
and Alaska, USA [23, 35] to 78.3% in children 
aged 5–14 years in Western Australia [44] 
(Appendix Table 1). One study reported an 
increase of 150.0% in children aged 5–17 years 
in a postvaccination period soon after the 
introduction of PCV7 [34]; in a later period, for 
Table 5  Impact on all-type IPD in all ages









Australia ( January 2005 for all)




1997–2001 7.5 2005–2007 4.8 –36.0
Hanna 2010 [43] All ages, 
nonaboriginal 
people 
2001–2004 9.3 2006–2009 6.1 –34.4
Europe
Foster 2011, UK  
(September 2006) [25]
All ages 2003–2005 8.3 2006–2009 7.5 –9.6
Miller 2011, UK  
(September 2006) [26]






1997–2003 4.0 2007–2008 3.2 –20.0
Harboe 2010, Denmark [12] All ages 2000–2007 19.6 2008 17.1 –12.8
Guevara 2009, Spain ( June 
2001: limited) [22]
All ages 2001–2002 15.8 2006–2007 16.3 +3.2
Rodenburg 2010, 
Netherlands  
( June 2006) [14]
All ages 2004–2006 15.0 2006–2008 15.9 +6.0
North America
Pilishvili 2010  
(late 2000) [33]
All ages 1998–1999 24.4 2007 13.5 –44.7
Singleton 2007  
( January 2001) [35]
All ages, 
nonnatives 
1995–2000 16.7 2004–2006 11.1 –33.5
IPD invasive pneumococcal disease, PCV7 7-valent pneumococcal conjugate vaccine, PPV23 23-valent pneumococcal 
polysaccharides vaccine
Adv Ther (2013)  30(2):127–51. 141
ranging from 7.1% in Denmark [12] to 44.1% 
in the USA [39]. In the remaining age groups, 
the increased rate reported ranged from 2.4% in 
the Netherlands [14] to 22.9% in Spain [17]. In 
one study from Canada, a reduction of 34.0% 
and an increase of 9.3% were reported for those 
aged 65–84 years and 85 year olds and older, 
respectively [42].
Impact on All-Type IPD and VT IPD 
Mortality
The impact of PCV7 vaccination on IPD 
mortality (both all-type [four studies] and VT 
[two studies]) was reported from North America 
only. One study reported reductions for VT IPD 
mortality across all age groups [33]. In another 
study, the reduction in VT IPD mortality in 
children less than 2 years observed was offset 
with an increase in non-VT IPD mortality 
resulting in no change [31]. Two studies 
reported reductions of 62.5% and 57.1% for all-
type IPD in vaccine-eligible children [33, 38]. 
Two studies reported an overall reduction in 
all-type IPD mortality in all ages of 37.8% and 
75.9% [38, 40]. There was a reduction in all-type 
IPD mortality for all the nonvaccine-eligible age 
groups reported ranging from 17.4% in those 
aged 50 years or older [30] to 50.0% in those 
aged 25–34 years [38].
DISCUSSION
The results from this review illustrate that PCV7 
has had a significant impact on IPD across all 
ages through its use in pediatric immunization 
programs. PCV7 vaccination leads to a reduction 
in VT IPD in vaccine-eligible children and 
also to an overall reduction in all-type IPD in 
these children. PCV7 was also shown to have 
an indirect impact on VT and all-type IPD in 
the overall population, although this impact is 
from 7.1% in those aged 30–49 years in Western 
Australia [44] to 90.8% in those aged 18–49 years 
in the USA [33].
All 13 studies reporting the impact for adults 
aged 65 years or older (with a total of 16 age 
groups) showed a reduction in the incidence of 
VT IPD ranging from 1.1% in the Netherlands [14] 
to 92.0% in the USA [33], with a median 
reduction of 53.8%.
Impact on All-Type IPD in Age Groups not 
Vaccine Eligible (Indirect Effect)
There was an overall decrease for 12 of the 
16 studies that reported data for nonvaccine-
eligible children aged from over 2 or over 5 
years to less than 17 years; the rate reduction 
ranged from 6.6% for children aged 2 years or 
older in the UK [25] to 53.4% in children aged 
2–4 years in Norway [15] (Appendix Table 2). 
In the five studies that reported an increase, 
the rate increase ranged from 9.1% in children 
aged 5–15 years in Germany [13] to 90.5% 
and 134.5% in children aged 5–17 years and 
2–4 years, respectively, in one hospital in 
Barcelona, Spain [23].
Fourteen studies reported data in 25 adult age 
groups (from 15/17 to 64 years old). The rates 
reported for 19 of these age groups ranged from a 
reduction of 2.0% in 15–64 year-old nonnatives 
in north Queensland, Australia [43] to 48.9% in 
18–44 year-old nonnatives in Alaska, USA [34]. 
In the six age groups in which an increased rate 
was reported, the increase ranged from 8.5% in 
nonnative 50–64 year olds in north Queensland, 
Australia [43] to 119.7% in 20–39 year olds in 
Alberta, Canada [41].
Seventeen studies reported data for those 
aged 65 years and over, with one study from 
Calgary, Canada reporting data for two age 
groups; 65–84 years and 85 years and over [42]. 
Reductions were reported in 12 of these studies, 
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lower than that seen in vaccine-eligible children. 
Despite the increase in non-VT IPD that has 
been reported, it has been insufficient generally 
to offset the reduction of VT IPD resulting in an 
overall reduction of all-type IPD.
The extent of the impact varied across 
the studies; many factors (and probably a 
combination of factors) contribute to explain 
this heterogeneity.
One of these factors is the sero-epidemiology 
of S. pneumoniae before the introduction of 
PCV7 and the match with the serotypes in 
PCV7. In the USA, the serotypes included in 
PCV7 matched the most prevalent serotypes 
responsible for IPD, but in other countries and 
regions, the percentage of IPD due to these seven 
serotypes varied; thus partly explaining the 
different impact observed [25, 32].
The process for PCV7 introduction, its 
uptake, the recommended schedule, and the 
implementation of a catch-up program or not 
also varied between countries. In the USA, 
where the impact was the greatest, there was a 
rapid and high uptake after introduction into 
the NIP for universal vaccination of children 
less than 2 years old with a 3 + 1 schedule [47]. 
However, there was a vaccine shortage in the 
early stages after introduction into the NIP, so 
uptake of all four doses was low during this 
period [48]. In Australia, PCV7 was funded in 
mid-2001 for indigenous children less than 
2 years of age, nonindigenous children living 
in central Australia, and for all children less 
than 5 years of age with predisposing medical 
conditions [44]. The recommended schedule 
was 3 + 0 (at 2, 4, and 6 months old) with 
no booster in the second year of life. Then in 
January 2005, PCV7 funding was extended to 
all children less than 2 years of age.
In Europe, although PCV7 received its 
licence in 2001, introduction into NIPs and 
funding varied widely. In some countries, 
such as the UK, following the introduction of 
PCV7 and reimbursement for all children under 
2 years of age in 2006 with a 2 + 1 schedule, 
uptake was rapid and high, with an estimated 
uptake rate from 84.7% in 2007–2008 to 
93% in 2009–2010 in the UK [49]. In other 
countries, such as France and Switzerland, 
PCV7 was introduced into the NIPs with a 3 
+ 1 schedule initially for at-risk children less 
than 2 years of age in France and under 5 years 
of age in Switzerland. In 2006, PCV7 was also 
recommended for all children under 2 years 
of age with a 2 + 1 schedule in France, and in 
Switzerland for healthy children under 2 years 
of age. In France, the incidence of all-type IPD 
in children less than 2 years was reduced by 
30% between 2001–2002 and 2007 [50]. In 
Switzerland, the number of children under 2 
years of age with all-type IPD was reduced from 
an average of 43 to 22 in 2009 (49% reduction) 
[51]. For the same periods, the reduction in VT 
IPD was 85% (from 27 to 4) while the number 
of non-VT IPD cases remained stable [51].
The periods chosen for prevaccination 
and postvaccination can also introduce 
variability in the estimated impact. It is 
difficult to differentiate changes that can occur 
independently of vaccination, such as natural 
evolution of circulating serotypes or antibiotic 
resistance, from changes due to vaccine-
induced serotype replacement, and it is possible 
that several factors may be responsible for the 
changes. Data from the USA show an evolution 
of impact with a greater distance from PCV7 
introduction for the postvaccination period. 
In Alaska, comparing the incidence of VT IPD 
in nonnative children under 2 years of age 
in 1995–2000 with that in 2001–2003 and 
2004–2006 showed reductions of 80.3% and 
97.7%, respectively (Table 2) [34, 35]. The same 
analysis for all-type IPD showed reductions 
of 61.7% and 67.8%, respectively. In another 
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USA dataset, the ABCs network, the analysis 
for 2001 just after the introduction of PCV7 
showed a 78.5% reduction in the incidence 
of VT IPD in children lesst than 2 years of age 
compared with the analysis for 2005, which 
showed almost 100% reduction [29, 32].
The studies analyzed in this review used 
different surveillance systems and case 
definitions; in addition, it is possible that 
changes in diagnosis and reporting practices 
occurred after the introduction of PCV7. 
The studies also varied in their geographical 
coverage, with some able to claim regional 
or national representation, while some 
reported data from one or two hospitals, 
which was the case for four studies from 
Spain [17, 20, 23, 24]. In addition, different 
schedules (3 + 1 and 2 + 1) were used with 
differing rates of uptake; for example, in 
Norway and the UK, there was a rapid uptake 
after introduction into the NIPs with a 2 + 1 
schedule, whereas in Spain there was a slow 
uptake after introduction through the private 
market with a 3 + 1 schedule.
Despite these limitations, this analysis 
generally confirms the impact of PCV7 on VT 
IPD and all-type IPD in vaccine-eligible children 
as well as an indirect impact on nonvaccine-
eligible age groups. Since 2010 many countries 
have decided to replace PCV7 with PCV13. The 
vaccine includes the seven serotypes present 
in PCV7 (i.e., 14, 4, 9V, 19F, 18C, 6B, and 23F), 
and offers potential additional protection 
against serotypes 1, 5, 7F, 19A, 6A, and 3. 
PCV13 has been shown to be well tolerated and 
immunogenic for all 13 serotypes [52]. Although 
no PCV13 impact study results have been 
published yet, in the UK where PCV13 replaced 
PCV7 in April 2010, preliminary data suggest 
that, up to July 2011, IPD due to PCV13-only 
serotypes has been reduced by 50% in children 
under 2 years of age [53].
CONCLUSION
It is important not to lose sight of the significant 
impact that PCV7 has had on IPD, despite the 
increase in non-VT IPD, but we need to remain 
vigilant for serotype replacement. With the 
introduction of PCV13 we can expect to see a 
reduction in the incidence of IPD due to the six 
additional serotypes included, as well as continued 
protection against IPD due to PCV7 serotypes. 
Robust surveillance systems are essential for the 
evaluation of the impact of PCV13 on all-type IPD 
and for monitoring the evolution of non-VT IPD.
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APPENDIX
Table 1  Impact on VT IPD reduction in nonvaccine-eligible populations























Hanna 2010 [43] Nonaboriginal 5–14 years 2001–2004 1.2 2006–2009 0.6 –50.0
Lehmann 2010 [44] Nonaboriginal 2–4 years 1997–2001 17.9 2005–2007 4.2 –76.5
Nonaboriginal 5–14 years 2.3 0.5 –78.3
Europe
Miller 2011, UK [26] 5–14 years 2000–2006 2.2 2009–2010 0.5 –77.3
Vestrheim 2008,  
Norway [15]
2–4 years 2004–2005 13.5 2007 7.5 –44.4
Munoz-Almagro 2008, 
Spain [23]
2–4 years 1997–2001 6.8 2002–2006 9.2 +35.3
5–17 years 0.5 0.3 –40.0
North America
Hennessy 2005 [34] Nonnative 2–4 years 1995–2000 13.6 2001–2003 7.5 –44.9
Nonnative 5–17 years 1.0 2.5 +150.0
Singleton 2007 [35] Nonnative 2–4 years 1995–2000 13.6 2004–2006 0 –100.0
Nonnative 5–17 years 1.0 0.6 –40.0
Kellner 2009 [42] 2–4 years 1998–2001 17.9 2003–2007 7.3 –59.2












Hanna 2010 [43] 15–64 years 2001–2004 3.1 2006–2009 1.2 –61.3
Lehmann 2010 [44] Nonaboriginal 15–29 
years








Miller 2011, UK [26] 15–44 years 2000–2006 3.3 2009–2010 0.4 –87.9
45–64 years 7.7 1.1 –85.7
Vestrheim 2010,  
Norway [16]
20–39 years 2004–2005 3.9 2008 3.1 –20.5
40–64 years 12.2 4.9 –59.8
Ardanuy 2009, Spain [17] 18–64 years 1997–2001 3.1 2005–2007 2.7 –12.9
Rodenburg 2010, 
Netherlands [14]
50–64 years 2004–2006 7.5 2006–2008 8.2 +9.3
Adv Ther (2013)  30(2):127–51. 145
Table 1  continued






Pilishvili 2010 [33] 18–49 years 1998–1999 7.6 2007 0.7 –90.8
50–64 years 12.8 1.7 –86.7
Hennessy 2005 [34] Nonnatives 18–44 years 1995–2000 4.3 2001–2003 1.1 –74.8
Singleton 2007 [35] Nonnatives 18–44 years 1995–2000 4.1 2004–2006 0.8 –80.5
Lexau 2005 [30] 50–64 years 1998–1999 12.9 2002–2003 6.9 –46.5
Whitney 2003 [29] 20–39 years 1998–1999 6.6 2001 4.0 –39.4
40–64 years 11.6 10.0 –13.8









Hanna 2010 [43] Nonaboriginal ≥65 years 2001–2004 12.5 2006–2009 2.8 –77.6
Lehmann 2010 [44] Nonaboriginal ≥65 years 1997–2001 12.6 2005–2007 6.5 –48.4
Europe
Miller 2011, UK [26] ≥65 years 2000–2006 18.2 2009–2010 3.4 –81.3
Guevara 2009, Spain [22] ≥65 years 2001–2002 11.8 2006–2007 3.7 –68.6
Vestrheim 2010,  
Norway [16]
≥65 years 2004–2005 42.4 2008 24.0 –43.4
Ardanuy 2009, Spain [17] ≥65 years 1997–2001 19.5 2005–2007 12.3 –36.9
Perez-Trallero 2009,  
Spain [24]
>64 years 1996–2001 20.2 2002–2007 17.0 –15.8
Rodenburg 2010, 
Netherlands [14]
≥65 years 2004–2006 28.2 2006–2008 27.9 –1.1
North America
Pilishvili 2010 [33] ≥65 years 1998–1999 33.7 2007 2.7 –92.0
Lexau 2005 [30] 65–74 years 1998–1999 21.6 2002–2003 10.2 –52.8
75–84 years 41.0 15.4 –62.4
≥85 years 69.2 31.3 –54.8
Hicks 2007 [31] ≥65 years 1998–1999 34.5 2004 8.2 –76.2
Whitney 2003 [29] >64 years 1998–1999 33.4 2001 23.9 –28.5
Kellner 2009 [42] 65–84 years 1998–2001 22.1 2003–2007 4.8 –72.3
≥85 years 29.1 22.5 –22.7
VT IPD vaccine-type invasive pneumococcal disease
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Table 2  Impact on all-type IPD in nonvaccine-eligible populations























Hanna 2010 [43] Nonaboriginal 5–14 years 2001–2004 2.5 2006–2009 1.2 –52.0
Lehmann 2010 [44] Nonaboriginal 2–4 years 1997–2001 21.2 2005–2007 9.9 –53.3
Nonaboriginal 5–14 years 2.8 1.7 –39.3
Europe
Verstrheim 2008,  
Norway [15]
2–4 years 2004–2005 23.6 2007 11.0 –53.4
Miller 2011, UK [26] 2–4 years 2000–2006 16.4 2009–2010 9.3 –43.3
5–14 years 5.1 3.0 –41.2
Aristegui 2007, Spain [18] 2–5 years 1998–2001 30.1 2002–2003 33.1 –10.0
Foster 2011, UK [25] ≥2 years 2003–2005 7.6 2006–2009 7.1 –6.6
Rückinger 2009,  
Germany [13]
5–15 years 1997–2003 1.1 2007–2008 1.2 +9.1
Harboe 2010,  
Denmark [12]
2–4 years 2000–2007 8.5 2008 11.8 +38.8
5–17 years 2.6 1.5 –42.3
Munoz-Almagro 2008, 
Spain [23]
2–4 years 1997–2001 11.3 2002–2006 26.5 +134.5
5–17 years 2.1 4.0 +90.5
North America
Pilishvili 2010 [33] 5–17 years 1998–1999 4.2 2007 2.4 –42.9
Hennessy 2005 [34] Nonnatives 5–17 years 1995–2000 3.9 2004–2006 4.6 +17.9
Singleton 2007 [35] Nonnatives 5–17 years 1995–2000 3.8 2001–2003 2.8 –26.3
Albrich 2007 [27] 5–17 years 1997–2000 3.9 2000–2004 3.3 –15.4
Tyrrell 2009 [41] 5–19 years 2000 2.4 2006 4.0 +66.7
Kellner 2009 [42] 2–4 years 1998–2001 22.7 2003–2007 12.6 –44.5
5–15 years 3.3 2.4 –27.3












Lehmann 2010 [44] Nonaboriginal 15–29 years 1997–2001 2.4 2005–2007 1.5 –37.5
Nonaboriginal 30–49 years 2.8 2.7 –3.6
Hanna 2010 [43] Nonaboriginal 50–64 years 2001–2004 4.7 2006–2009 5.1 +8.5
Nonaboriginal 15–64 years 5.0 4.9 –2.0
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Miller 2011, UK [26] 15–44 years 2000–2006 8.3 2009–2010 4.7 –43.4
45–64 years 17.9 11.0 –38.5
Harboe 2010,  
Denmark [12]
18–49 years 2000–2007 7.1 2008 5.8 –18.3
50–64 years 23.5 19.6 –16.6
Rodenburg 2010, 
Netherlands [14]
50–64 years 2004–2006 16.7 2006–2008 18.5 +10.8
Ardanuy 2009, Spain [17] 18–64 years 1997–2001 8.4 2005–2007 12.5 +48.8
North America
Hennessy 2005 [34] Nonnative 18–44 years 1995–2000 9.2 2001–2003 4.7 –48.9
Nonnative ≥45 years 23.5 16.9 –28.1
Singleton 2007 [35] Nonnative 18–44 years 1995–2000 9.1 2004–2006 6.2 –31.9
Nonnative ≥45 years 24.3 18.4 –24.3
Albrich 2007 [27] 18–39 years 1997–2000 11.7 2000–2004 6.9 –41.0
40–64 years 23.0 17.2 –25.2
Whitney 2003 [29] 20–39 years 1998–1999 11.2 2001 7.6 –32.1
40–64 years 21.5 19.7 –8.4
Tyrrell 2009 [41] 20–39 years 2000 6.1 2006 13.4 +119.7
40–64 years 11.2 20.9 +86.6
Pilishvili 2010 [33] 18–49 years 1998–1999 13.3 2007 8.0 –39.8
50–64 years 24.0 19.8 –17.5
Kellner 2009 [42] 16–64 years 1998–2001 7.1 2003–2007 12.3 +73.2
Simonsen 2011 [39] 18–39 years 1996–1999 3.5 2005–2006 1.4 –60.0









Hanna 2010 [43] Nonaboriginal ≥65 years 2001–2004 23.0 2006–2009 14.1 –38.7
Lehmann 2010 [44] Nonaboriginal ≥65 years 1997–2001 19.9 2005–2007 13.0 –34.7
Europe
Miller 2011, UK [26] ≥65 years 2000–2006 34.8 2009–2010 28.2 –19.0
Harboe 2010,  
Denmark [12]
≥65 years 2000–2007 65.9 2008 61.2 –7.1
Rodenburg 2010, 
Netherlands [14]
≥65 years 2004–2006 58.8 2006–2008 60.2 +2.4
Guevara 2009, Spain [22] ≥65 years 2001–2002 32.4 2006–2007 33.7 +4.0
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Perez-Trallero 2009,  
Spain [24]
>64 years 1996–2001 50.7 2002–2007 55.6 +9.7
Ardanuy 2009, Spain [17] ≥65 years 1997–2001 45.8 2005–2007 56.3 +22.9
North America
McBean 2005 [37] ≥65 years 1996–2000 36.8 2002–2003 21.8 –40.8
Hicks 2007 [31] ≥65 years 1998–1999 61.5 2004 38.0 –38.2
Pilishvili 2010 [33] ≥65 years 1998–1999 60.1 2007 37.9 –36.9
Lexau 2005 [30] ≥50 years 1998–1999 40.8 2002–2003 29.4 –27.9
Albrich 2007 [27] ≥65 years 1997–2000 65.4 2000–2004 48.2 –26.3
Whitney 2003 [29] ≥65 years 1998–1999 60.1 2001 49.5 –17.6
Tyrrell 2009 [41] ≥65 years 2000 28.2 2006 23.0 –18.4
Kellner 2009 [42] 65–84 years 1998–2001 36.2 2003–2007 23.9 –34.0
≥85 years 55.0 60.1 +9.3
Simonsen 2011 [39] ≥65 years 1996–1999 30.6 2005–2006 17.1 –44.1
IPD invasive pneumococcal disease
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